Skip to main content
. 2018 Nov 27;37(3):391–405. doi: 10.1007/s40273-018-0745-z

Fig. 3.

Fig. 3

One-way sensitivity analysis: tornado diagrams for the ICER or NMB of the following comparisons: gBRCAmut: a niraparib versus RS, b niraparib versus olaparib, c niraparib versus rucaparib; non-gBRCAmut: d niraparib versus RS, e niraparib versus olaparib, f niraparib versus rucaparib. ICER incremental cost-effectiveness ratio, NMB net monetary benefit, OS overall survival, PD progressed disease, PFS progression-free survival, RS routine surveillance, TOMT time on maintenance treatment